MHRA clears inavolisib, offering new option for returning breast cancer
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Abdomen-pelvis CT is the nation’s highest-volume CT category
The receipt of this order further strengthens the company's position in the global pharmaceutical market
The audit was completed with zero critical and zero major observations
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
GLP-1 therapies are among the fastest-growing drug classes worldwide, projected to drive a $95 billion obesity market by 2030
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
Subscribe To Our Newsletter & Stay Updated